Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the transaction, the chief financial officer owned 150,503 shares in the company, valued at approximately $18,709,027.93. The trade was a 1.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Gilead Sciences Stock Performance

Shares of GILD traded up $3.65 during midday trading on Friday, reaching $124.91. The stock had a trading volume of 10,638,850 shares, compared to its average volume of 6,570,563. Gilead Sciences, Inc. has a one year low of $91.68 and a one year high of $128.70. The firm has a market cap of $154.97 billion, a PE ratio of 19.37, a P/E/G ratio of 0.65 and a beta of 0.33. The firm has a 50 day simple moving average of $123.24 and a 200-day simple moving average of $117.92. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter last year, the company posted $2.02 EPS. Gilead Sciences’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Scotiabank began coverage on shares of Gilead Sciences in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 target price on the stock. BMO Capital Markets reaffirmed an “outperform” rating on shares of Gilead Sciences in a research report on Tuesday. Daiwa Capital Markets upped their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. Finally, Sanford C. Bernstein set a $135.00 target price on Gilead Sciences and gave the stock an “outperform” rating in a research note on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $133.16.

Institutional Trading of Gilead Sciences

Several hedge funds have recently added to or reduced their stakes in GILD. GoalVest Advisory LLC boosted its stake in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC purchased a new position in shares of Gilead Sciences in the third quarter worth $26,000. Harbor Asset Planning Inc. bought a new position in Gilead Sciences during the 2nd quarter valued at about $27,000. Putney Financial Group LLC boosted its holdings in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the last quarter. Finally, Howard Hughes Medical Institute purchased a new position in shares of Gilead Sciences in the 2nd quarter worth $30,000. 83.67% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.